AstraZeneca and Oracle want AI to find the patients drug trials can't, starting with blood pressure in Abu Dhabi

AstraZeneca and Oracle Health and Life Sciences said on Tuesday, Oct. 20, 2026, that they will test using AI and de-identified real-world patient data to speed up clinical-trial recruitment, spot drug-safety problems and get patients diagnosed sooner, starting with a program for uncontrolled high blood pressure in Abu Dhabi with local health company M42.

Drug trials fail or crawl for a boring reason: they can't find enough of the right patients fast enough. Oracle owns a huge pile of hospital records through Cerner, and AstraZeneca has a pipeline that needs patients, so the match makes sense on paper. The skeptic's checklist is short: it's non-binding, nobody is putting a number on it, and the patient data comes from health systems who have to sign off project by project. Starting with blood pressure in Abu Dhabi, where Oracle already has an M42 partnership, is a careful first test. If it works there, expect this pitch in a lot more hospital systems.

AstraZeneca and Oracle Health and Life Sciences signed a non-binding term sheet to explore putting AstraZeneca's scientific, clinical-development and regulatory work together with Oracle's real-world data, cloud infrastructure and AI-enabled clinical tools. A term sheet is an outline of a deal. Non-binding means neither side is locked into building the projects yet. No financial terms were disclosed. Those lines are the companies'.

The first uses they named are clinical-trial recruitment, meaning finding eligible patients earlier; earlier diagnosis; drug-safety monitoring; and real-world evidence across a medicine's life. Real-world evidence is what patient records show outside a formal trial. Programs are meant to span AstraZeneca's core areas: oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare disease. Those areas are AstraZeneca's.

Projects are planned in the United States, the Middle East and Europe, working with local governments. The first program is hypertension care and research in Abu Dhabi with the health company M42. Hypertension is high blood pressure. The aim is to help clinical teams find patients whose blood pressure is still uncontrolled, follow guideline-directed care, and improve trial recruitment. pharmaphorum reports that Oracle already worked with M42 last year on unified patient records in the UAE. Those lines are the companies' and pharmaphorum's.

On privacy, the companies say the work uses de-identified real-world data, meaning records with the details that identify a person removed. AstraZeneca says it will not receive patient-identifiable information. Each project is reviewed on its own and goes ahead only once legal, privacy, regulatory, ethical and institutional safeguards are in place. Oracle says the companies plan shared governance and agreed measures of success, and will use those to decide whether an approach that works should extend to other diseases and countries. Those lines are the companies'.

AstraZeneca chief executive Pascal Soriot said the collaboration "brings leaders in healthcare and AI together at a global scale" and that "we can help clinicians identify patients sooner, optimise clinical trials, and generate evidence continuously across the lifecycle of a medicine." Oracle chief executive Mike Sicilia said "Some of the most important opportunities for AI are in healthcare." AstraZeneca's chief digital, data and AI officer, Anne-Claire Gerbaldi, said "Too many patients are diagnosed late or face a long journey to get the care they need." Oracle Health and Life Sciences head Seema Verma said the work happens "under the governance of the health systems delivering care." Those quotations are theirs, as the companies print them. Soriot discussed the Abu Dhabi program on CNBC the same day.

Fierce Biotech calls patient recruitment one of the eternal problems of drug development. The announcements do not give a deal value, a number of patients, a start date, or any results. The term sheet is an agreement to explore the work. It is not a report that a project has already produced findings.

In plain terms, AstraZeneca and Oracle said on Tuesday that they will try using AI and stripped patient records to find trial patients faster, catch safety problems, and diagnose people sooner. The first test is uncontrolled high blood pressure in Abu Dhabi, with M42. Nothing has been priced, and nothing in the announcements says a project is already producing results.